News | January 24, 2014

Nanoparticle Therapy Reduces Damage After Heart Attack

January 24, 2014 — Cour Pharmaceutical Development Co. Inc. published data in Science Translational Medicine showing the potential of immune modifying nanoparticles (IMP) to reduce inflammation and promote tissue repair and regeneration in patients who have suffered a heart attack.
Animal models injected with IMPs after a heart attack experienced heart lesions reduced by 50 percent, which allowed the heart to pump significantly more blood. IMP treatment showed reduced inflammation and promoted regeneration in all models tested.
The particles are compositions based on polylactic-co-glycolic acid, a biocompatible and biodegradable substance already approved by the U.S. Food and Drug Administration (FDA) for use in a range of therapeutics.
The therapy also showed efficacy in numerous other inflammatory models, specifically in West Nile Virus, encephalitis, peritonitis, multiple sclerosis and inflammatory bowel disease. 
For more information: 

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init